TY - JOUR
T1 - Genetic causes of surfactant protein abnormalities
AU - Nogee, Lawrence M.
N1 - Funding Information:
The author gratefully acknowledge the collaboration of Drs Jeffrey Whitsett and Susan Wert (Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine), Aaron Hamvas (Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine), and Jennifer Wambach, and F. Sessions Cole (St. Louis Children’s Hospital and Washington University in St. Louis). Supported by US National Institutes of Health, 1UO1HL134745, and the Eudowood Foundation. L.M.N. receives royalties from Wolters Kluwer Health for coauthoring a contribution to UpToDate, and is a site coinvestigator on clinical trial for neonatal pulmonary hypertension funded by United Therapeutics.
Publisher Copyright:
© 2019 Lippincott Williams and Wilkins. All rights reserved.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Purpose of review Mutations in genes encoding proteins critical for the production and function of pulmonary surfactant cause diffuse lung disease. Timely recognition and diagnosis of affected individuals is important for proper counseling concerning prognosis and recurrence risk. Recent findings Involved genes include those encoding for surfactant proteins A, B, and C, member A3 of the ATP-binding cassette family, and for thyroid transcription factor 1. Clinical presentations overlap and range from severe and rapidly fatal neonatal lung disease to development of pulmonary fibrosis well into adult life. The inheritance patterns, course, and prognosis differ depending upon the gene involved, and in some cases the specific mutation. Treatment options are currently limited, with lung transplantation an option for patients with end-stage pulmonary fibrosis. Additional genetic disorders with overlapping pulmonary phenotypes are being identified through newer methods, although these disorders often involve other organ systems. Summary Genetic disorders of surfactant production are rare but associated with significant morbidity and mortality. Diagnosis can be made invasively through clinically available genetic testing. Improved treatment options are needed and better understanding of the molecular pathophysiology may provide insights into treatments for other lung disorders causing fibrosis.
AB - Purpose of review Mutations in genes encoding proteins critical for the production and function of pulmonary surfactant cause diffuse lung disease. Timely recognition and diagnosis of affected individuals is important for proper counseling concerning prognosis and recurrence risk. Recent findings Involved genes include those encoding for surfactant proteins A, B, and C, member A3 of the ATP-binding cassette family, and for thyroid transcription factor 1. Clinical presentations overlap and range from severe and rapidly fatal neonatal lung disease to development of pulmonary fibrosis well into adult life. The inheritance patterns, course, and prognosis differ depending upon the gene involved, and in some cases the specific mutation. Treatment options are currently limited, with lung transplantation an option for patients with end-stage pulmonary fibrosis. Additional genetic disorders with overlapping pulmonary phenotypes are being identified through newer methods, although these disorders often involve other organ systems. Summary Genetic disorders of surfactant production are rare but associated with significant morbidity and mortality. Diagnosis can be made invasively through clinically available genetic testing. Improved treatment options are needed and better understanding of the molecular pathophysiology may provide insights into treatments for other lung disorders causing fibrosis.
KW - Alveolar proteinosis
KW - Interstitial lung disease
KW - Neonatal respiratory distress syndrome
KW - Pulmonary fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85066880273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066880273&partnerID=8YFLogxK
U2 - 10.1097/MOP.0000000000000751
DO - 10.1097/MOP.0000000000000751
M3 - Review article
C2 - 31090574
AN - SCOPUS:85066880273
SN - 1040-8703
VL - 31
SP - 330
EP - 339
JO - Current opinion in pediatrics
JF - Current opinion in pediatrics
IS - 3
ER -